Damora Therapeutics, Inc. (DMRA) Ownership
DMRA ownership summary
as of October 18, 2026- Institutions
- 106.0% of shares outstanding
- Insiders
- 8.43% of shares outstanding
- Shares outstanding
- 61.7M
- Float
- 40.9M shares available to trade
- Short interest
- 8.95% 4.7M shares short
- Days to cover
- 6.09 short interest up 0.0% vs prior month
- Institutions 106.02%
- Insiders 8.43%
DMRA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.96% | 9.2M | $170.3M | +187,498 (+2.1%) | June 30, 2026 |
| 2 | venBio Select Advisor LLC | 6.13% | 3.8M | $69.8M | — | June 30, 2026 |
| 3 | BlackRock Inc | 5.12% | 3.2M | $58.3M | +2.9M (+1,321.6%) | June 30, 2026 |
| 4 | HHG PLC | 3.83% | 2.4M | $43.6M | +2.4M (+135,765.2%) | March 31, 2026 |
| 5 | Viking Global Investors LP | 3.74% | 2.3M | $42.6M | — | June 30, 2026 |
| 6 | Remedium Capital Partners, LLC | 3.31% | 2.0M | $37.7M | — | June 30, 2026 |
| 7 | COMMODORE CAPITAL LP | 3.14% | 1.9M | $35.8M | — | June 30, 2026 |
| 8 | BRAIDWELL LP | 2.62% | 1.6M | $29.9M | +725,531 (+81.1%) | June 30, 2026 |
| 9 | Bellevue Group AG | 2.62% | 1.6M | $29.9M | −679,154 (−29.6%) | June 30, 2026 |
| 10 | State Street Corp | 2.50% | 1.5M | $28.5M | +1.4M (+740.3%) | June 30, 2026 |
| 11 | Balyasny Asset Management LLC | 1.99% | 1.2M | $22.7M | −218,873 (−15.1%) | June 30, 2026 |
| 12 | Perceptive Advisors LLC | 1.98% | 1.2M | $22.6M | — | June 30, 2026 |
| 13 | Wellington Management Company LLP | 1.71% | 1.1M | $19.5M | — | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 1.56% | 965K | $17.8M | +724,238 (+300.4%) | June 30, 2026 |
| 15 | Siren, L.L.C. | 1.46% | 900K | $16.6M | — | June 30, 2026 |
| 16 | UBS Group AG | 1.36% | 840K | $15.5M | +679,877 (+423.8%) | June 30, 2026 |
| 17 | Vestal Point Capital LP | 0.93% | 575K | $10.6M | −25,000 (−4.2%) | June 30, 2026 |
| 18 | Vanguard Portfolio Management, LLC | 0.59% | 365K | $6.7M | +365,499 (0.0%) | June 30, 2026 |
| 19 | Northern Trust Corp | 0.58% | 360K | $6.6M | +320,823 (+825.1%) | June 30, 2026 |
| 20 | The Goldman Sachs Group Inc | 0.55% | 339K | $6.3M | +251,043 (+284.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 9.9M shares and 3 cut 923K.
DMRA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 2.97% | 1.8M | $33.8M | +8,400 (+0.5%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.99% | 1.2M | $22.6M | −14,144 (−1.1%) | September 30, 2026 |
| 3 | Fidelity Small Cap Growth | 1.35% | 834K | $15.4M | — | July 31, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 1.18% | 728K | $13.4M | −13,900 (−1.9%) | September 30, 2026 |
| 5 | JPMorgan Small Cap Growth A | 1.15% | 710K | $13.1M | −20,949 (−2.9%) | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.95% | 584K | $10.8M | +4,952 (+0.9%) | July 31, 2026 |
| 7 | Fidelity Growth Company K6 | 0.88% | 540K | $10.0M | +2,600 (+0.5%) | August 31, 2026 |
| 8 | Fidelity Select Health Care | 0.81% | 500K | $9.2M | — | August 31, 2026 |
| 9 | Fidelity Series Growth Company | 0.74% | 455K | $8.4M | +2,099 (+0.5%) | August 31, 2026 |
| 10 | Fidelity Select Biotechnology | 0.74% | 455K | $8.4M | — | August 31, 2026 |
| 11 | JPM Global Healthcare C acc USD | 0.69% | 429K | $7.9M | −6,146 (−1.4%) | August 31, 2026 |
| 12 | Fidelity Small Cap Growth K6 | 0.66% | 410K | $7.6M | — | July 31, 2026 |
| 13 | Fidelity Stock Selector Small Cap | 0.65% | 403K | $7.4M | — | July 31, 2026 |
| 14 | Fidelity Series Small Cap Opps | 0.50% | 308K | $5.7M | — | July 31, 2026 |
| 15 | Vanguard Russell 2000 ETF | 0.50% | 307K | $5.7M | +7,258 (+2.4%) | August 31, 2026 |
| 16 | iShares Russell 2000 Growth ETF | 0.50% | 306K | $5.6M | −387 (−0.1%) | September 30, 2026 |
| 17 | Fidelity Advisor Biotechnology I | 0.48% | 298K | $5.5M | — | August 31, 2026 |
| 18 | Fidelity Advisor Health Care I | 0.45% | 280K | $5.2M | — | August 31, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.42% | 262K | $4.8M | +171 (+0.1%) | September 30, 2026 |
| 20 | JPMorgan Small Cap Blend A | 0.37% | 228K | $4.2M | −4,182 (−1.8%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
DMRA insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | Hans T Schambye | Sell | $21.38 | 700 | $14,966 |
| 2026-01-02 | Lori Firmani | Sell | $21.41 | 135 | $2,890 |
| 2025-07-03 | Hans T Schambye | Sell | $3.38 | 735 | $2,484 |
| 2025-07-03 | Lori Firmani | Sell | $3.39 | 147 | $498 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
DMRA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns DMRA
Institutional investors own 106.0% of Damora Therapeutics's shares and insiders 8.43%. The largest holder is FMR Inc with 14.96% of the shares (9.2M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 3 reduced their stake in the latest filings. Short interest is 8.95% of the float, or 6.09 days of average trading volume. The share count rose 64.1% since 2019.
Related: DMRA analyst forecast, DMRA key metrics. See the DMRA stock overview for the latest quote and news.
DMRA ownership FAQ
Who owns the most Damora Therapeutics stock?
The largest shareholders of Damora Therapeutics are FMR Inc (14.96%), venBio Select Advisor LLC (6.13%), BlackRock Inc (5.12%), HHG PLC (3.83%), Viking Global Investors LP (3.74%).
What percentage of Damora Therapeutics is owned by institutions?
Institutions hold 106.0% of Damora Therapeutics's shares outstanding; insiders hold 8.43%.
Which funds own Damora Therapeutics?
The largest fund holders of Damora Therapeutics are Fidelity Growth Company Fund (2.97%), iShares Russell 2000 ETF (1.99%), Fidelity Small Cap Growth (1.35%), State Street® SPDR® S&P® Biotech ETF (1.18%), JPMorgan Small Cap Growth A (1.15%).
What is Damora Therapeutics's short interest?
4.7M shares of Damora Therapeutics were sold short, 8.95% of the float; at the average daily volume it would take 6.09 days to cover.
Are insiders buying or selling Damora Therapeutics?
Of the latest 4 reported insider transactions in Damora Therapeutics (since July 3, 2025), 0 were purchases and 4 were sales.
How many shares of Damora Therapeutics are outstanding?
Damora Therapeutics has 61.7M shares outstanding, of which 40.9M are in the public float.